Zobrazeno 1 - 10
of 88
pro vyhledávání: '"35"'
Autor:
N Rueth, Karen K. Swenson, M Knaack, Janet Krueger, Barbara Susnik, P Martone, SR Baldinger, Michaela Tsai, Erin Grimm, Tamera J. Lillemoe
Publikováno v:
Cancer Research. 79:P5-10
Background: While breast cancer is rare in women ≤ age 35, patients in this age group are more frequently diagnosed with aggressive cancer subtypes and pathologic germline mutations in cancer susceptibility genes than older patients. Higher recurre
Publikováno v:
Cancer Research. 81:PS11-21
BACKGROUND: As of June 2020, more than 2.5 million cases of COVID-19 and over 125,000 deaths related to COVID-19 have been confirmed in the United States (US). A strained healthcare system, quarantine orders, and national social distancing guidelines
Autor:
Tanja Fehm, Luc Dirix, Stefan Sleijfer, Paola Gazzaniga, José A. García-Sáenz, Carlos Caldas, Rita Zamarchi, Karthik V. Giridhar, Lorenzo Gerratana, Massimo Cristofanilli, Luis Manso, Dimitrios Mavroudis, Kostandinos Sideras, Meredith M. Regan, Zefei Jiang, Michail Ignatiadis, Rafael Gisbert-Criado, William E. Barlow, François-Clément Bidard, Thomas W. P. Friedl, Klaus Pantel, Evi Lianidou, Daniele Generali, Jean-Yves Pierga, Sabine Riethdorf, Tracy C. Yab, Mark Jesus M. Magbanua, Jose Vidal-Martinez, Jeffrey B. Smerage, Brigitte Rack, Hope S. Rugo, Catherine Alix-Panabières, Lisa A. Carey, Minetta C. Liu, Volkmar Müller, William Jacot, Wolfgang Janni, Elisabetta Munzone, Justin Stebbing, Leon W.M.M. Terstappen, Daniel F. Hayes
Publikováno v:
Cancer Research. 81:GS4-08
Background: Several studies suggest clinical utility of serial circulating tumor cell (CTC) enumeration as a means of assessing response status in metastatic breast cancer (MBC). The aim of this study is to conduct a comprehensive pooled analysis com
Publikováno v:
Cancer Research. 80:P4-14
Introduction: Breast cancer continues to be the most common cancer diagnosed in pregnant women. Management of breast cancer in pregnant patients requires finding a fine balance between treating the pregnant patient adequately while minimizing toxicit
Autor:
Burak Gumuscu, Abhishek Joshi, P. Zhang, Rene Gonzalez Mendoza, Salem Billan, Laurent Mortier, Jacob Schachter, Åse Bratland, Brett G.M. Hughes, Osama Roshdy, Jean-Jacques Grob, Eva Muñoz-Couselo, Ana Arance, Ramona F. Swaby, Florent Grange, Ralf Gutzmer, Nicolas Meyer
Publikováno v:
Cancer Research. 81:CT006-CT006
Background: In the multicenter, open-label, nonrandomized, phase 2 KEYNOTE-629 trial, pembro has demonstrated clinically meaningful and durable antitumor activity with a manageable safety profile for R/M cSCC based on the first interim analysis (IA).
Autor:
Yanina Natanzon, Joseph R. Burkhart, Ronda G. Broome, Anna B. Berry, Michael A. Thompson, Francesca Coutinho, Mahder Teka, Antony Ruggeri, Louise E. Widmer, Thomas D. Brown, James L. Weese, Chenan Zhang, Jennifer J Godden, Douglas J. Reding, Mary Tran
Publikováno v:
Cancer Research. 81:2618-2618
Background: National Comprehensive Cancer Network guidelines have recommended metastatic colorectal cancer patients (mCRC pts) undergo BRAF, KRAS, NRAS, and microsatellite instability/mismatch repair deficiency (MSI/MMR) testing since 2015. Previous
Autor:
Jutta John, Edith Weigert, Volker Hanf, C. Thomssen, Christoph Uleer, Carolin Hartung, T Lantzsch, Susanne Peschel, K-F Bürrig, EJ Kantelhardt, Martina Vetter, Joerg Buchmann
Publikováno v:
Cancer Research. 77:P2-05
Introduction The PiA-study (Prognostic assessment in routine Application, NCT 01592825) was designed as a representative cohort of breast cancer patients to estimate the proportions of traditional and modern prognostic factors. The ASCO-recommended b
Autor:
T Mancuso, T Graham, Karen Ott, Paul Hewitt, Andrea Eisen, J Lorentz, M Emmerson, Jacques Raphael
Publikováno v:
Cancer Research. 76:P6-10
Background Women with identified BRCA1/2 mutation have a substantially increased risk of developing several types of cancer, mainly breast and ovarian, during their lifetime. Management options included close surveillance, chemoprevention and prophyl
Autor:
Shah Rahimian, Asim Ali, Erkut Borazanci, Peter M. Anderson, Vivek Subbiah, Rolf Hultsch, Sri Chunduru, Alain Algazi, Corinne Maurice-Dror, Igor Puzanov, Hani M. Babiker, Nadia Caplan, Chantale Bernatchez, Ravi Murthy, Gregory Woodhead, Daniel Hendler, Jacob Schachter, Michal Lotem, Cara Haymaker, Adi Diab, Charles Hennemeyer, Hans Minderman
Publikováno v:
Cancer Research. 80:CT134-CT134
Background: Tilsotolimod, an investigational Toll-like receptor 9 (TLR9) agonist, modulates the tumor immune microenvironment and has single-agent antitumor activity in preclinical models. The ILLUMINATE-101 phase 1b study (NCT03052205) explored the
Publikováno v:
Cancer Research. 75:P6-09
INTRODUCTION: More than 60,000 women are diagnosed with ductal carcinoma in situ (DCIS) annually and offered the option of breast conserving surgery (BCS), often including radiation (RT) to reduce local recurrence. Although the incidence of radiation